Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,039.11
-6.26 (-0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
379,260
Open
1,046.50
Bid (Size)
1,010.00 (1)
Ask (Size)
1,046.00 (1)
Prev. Close
1,045.37
Today's Range
1,036.00 - 1,052.34
52wk Range
684.80 - 1,052.34
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
June 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
June 13, 2024
Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.
Via
Benzinga
Performance
YTD
+14.82%
+14.82%
1 Month
+5.25%
+5.25%
3 Month
+7.83%
+7.83%
6 Month
+22.48%
+22.48%
1 Year
+33.01%
+33.01%
More News
Read More
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
June 13, 2024
Via
Investor's Business Daily
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
June 12, 2024
Via
Investor's Business Daily
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
June 11, 2024
Via
Benzinga
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
June 04, 2024
Via
Benzinga
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
June 04, 2024
Via
Benzinga
2 Biotech Stocks to Buy in May
May 25, 2024
Via
The Motley Fool
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
June 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
Via
Benzinga
Stock Split Watch: 3 Growth Stocks That Could Be Next
June 07, 2024
Via
The Motley Fool
What's Going On With FibroGen Stock Tuesday?
June 04, 2024
Via
Benzinga
Exposures
Product Safety
FibroGen Stock Is Surging After The Bell: What's Going On?
June 03, 2024
Via
Benzinga
Exposures
Product Safety
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
May 20, 2024
Via
Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
June 03, 2024
Via
Benzinga
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
May 31, 2024
Via
Benzinga
Exposures
Product Safety
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
What's Going On With Biohaven Stock Wednesday?
May 29, 2024
Via
Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
May 24, 2024
Via
Benzinga
Topics
Data Breach
Exposures
Information Security
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
May 23, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
May 23, 2024
Via
The Motley Fool
Large Cap Biopharmaceuticals Performance
May 20, 2024
Via
Talk Markets
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
May 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.